PhillipCapital analyst Paul Chew has reiterated his ‘buy’ rating for iX Biopharma with an unchanged target price of 44.5 cents in a June 14 research note.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply